下调的 TICAM1 是一种预后生物标志物，与威尔姆斯瘤患者的免疫耐受有关。
Downregulated TICAM1 is a prognostic biomarker and associated with immune tolerance of Wilms tumor patients.
机构信息
Department of Pediatric Surgery, Qilu Hospital of Shandong University, Jinan 250000, Shandong, China.
出版信息
BMC Med Genomics. 2022 Aug 6;15(1):174. doi: 10.1186/s12920-022-01326-5.
BACKGROUND
TIR domain containing adaptor molecule 1 (TICAM1) is a coding gene participating in immune and inflammation responses to malignant cells. However, the role of TICAM1 in Wilms tumor (WT) is rarely known.
MATERIALS AND METHODS
The expression level of TICAM1 was calculated in the WT TARGET cohort and validated using the GSE66405 cohort. The Kaplan-Meier method was employed to investigate the potential clinical value of TICAM1 and the association between its expression level and clinical features. The influence of TICAM1 on immune infiltration was examined by ESTIMATE, CIBERSORT and MCPcounter algorithms. IC50 of chemotherapeutic drugs was calculated by "pRRophetic" R package.
RESULTS
TICAM1 was downregulated in WT patients with worse prognosis and a more advanced clinical stage. Moreover, a low expression level of TICAM1 contributed to less immune cell infiltration, few protective immune cells and more antitumor immune cells.
CONCLUSIONS
TICAM1 exerts a significant impact on the prognosis, progression and immune infiltration condition of WT.
背景
TIR 结构域包含衔接分子 1（TICAM1）是参与免疫和炎症反应恶性细胞的编码基因。然而，TICAM1 在肾母细胞瘤（WT）中的作用鲜为人知。
材料和方法
在 WT TARGET 队列中计算 TICAM1 的表达水平，并使用 GSE66405 队列进行验证。采用 Kaplan-Meier 法探讨 TICAM1 的潜在临床价值及其表达水平与临床特征的关系。通过 ESTIMATE、CIBERSORT 和 MCPcounter 算法检测 TICAM1 对免疫浸润的影响。通过“pRRophetic”R 包计算化疗药物的 IC50。
结果
TICAM1 在 WT 患者中表达下调，预后较差，临床分期较晚。此外，TICAM1 低表达与较少的免疫细胞浸润、较少的保护性免疫细胞和更多的抗肿瘤免疫细胞有关。
结论
TICAM1 对 WT 的预后、进展和免疫浸润状况有显著影响。
Zotero 插件